

## INFORMATION DISCLOSURE STATEMENT



FORM PTO 1449 (modified)  
U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
LIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)  
Date Submitted to PTO: May 28, 2008

ATTY DOCKET NO.  
2006\_1150A

SERIAL NO.  
10/586,499

APPLICANT  
Kyogo ITOH et al.

FILING DATE  
April 27, 2007

GROUP  
1614

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BA	00/18895	4/2000	WO			
	BB	2004/067029	8/2004	WO			Abstract
	BC						
	BD						
	BE						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Y. Lu et al., "Immunogene Therapy of Tumors with Vaccine Based on Xenogeneic Epidermal Growth Factor Receptor", The Journal of Immunology, Vol. 170, No. 6, pp. 3162-3170, March 15, 2003.
CB	H. Takedatsu et al., "Expression of Epithelial Cancer-Related Antigens in Hematologic Malignancies Applicable for Peptide-Based Immunotherapy", Journal of Immunotherapy, Vol. 27, pp. 289-297, 1997.
CC	T. Mine et al., "Immunological Evaluation of CTL Precursor-Oriented Vaccines for Advanced Lung Cancer Patients", Cancer Science, Vol. 94, No. 6, pp. 548-556, June 6, 2003.
CD	G. Gonzalez et al., "Epidermal Growth Factor-Based Cancer Vaccine for Non-Small-Cell Lung Cancer Therapy", Annals of Oncology, Vol. 14, No. 3, pp. 461-466, March 2003.
CE	R. S.Herbst et al., "Targeting the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer", Clinical Cancer Research, Vol. 9, pp. 5813-5824, December 1, 2003.
CF	H. Shomura et al., "Identification of Epidermal Growth Factor Receptor-Derived Peptides Immunogenic for HLA-A2 <sup>+</sup> Cancer Patients", British Journal of Cancer, Vol. 90, No. 8, pp. 1563-1571, April 19, 2004.
CG	

EXAMINER

DATE CONSIDERED